Maybridge and Strakan join forces to develop compounds active at a member of the steroid hormone receptor superfamily, newly identified as a modulator of bone formation
Maybridge, a producer and supplier of organic compounds for drug discovery and development in the pharmaceutical, biotechnology and agrochemical industries, and Strakan, an independent specialty pharmaceutical company, have announced that they will collaborate on an exclusive lead discovery effort. "Maybridge is pleased to have this chance to work with a biotech pioneer like Strakan," said Nick Kerton, chief executive officer.
"Strakan's work in degenerative bone disease is on the cutting-edge and Maybridge is very excited to lend its expertise to the development of new therapeutic agents." Strakan's product development portfolio is built around four drug delivery technologies, each of which give rise to a number of lead development projects which either address unmet clinical needs or provide advances over present treatments.
At the same time, they offer the potential for significant commercial opportunities arising from the future development of novel, innovative products.
Maybridge will develop a library of compounds active at a member of the steroid hormone receptor superfamily, newly identified by Strakan as a modulator of bone formation.
"These ligands will represent a new class of therapeutic agents for the treatment of degenerative bone disease," said Wayne Bowler, Strakan's bone research manager.
